BAUSCH HEALTH AMERICAS, INC.
🇺🇸United States
Clinical Trials
209
Active:5
Completed:171
Trial Phases
5 Phases
Phase 1:39
Phase 2:43
Phase 3:82
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (197 trials with phase data)• Click on a phase to view related trials
Phase 3
82 (41.6%)Phase 2
43 (21.8%)Phase 1
39 (19.8%)Phase 4
23 (11.7%)Not Applicable
10 (5.1%)A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing
Not Applicable
Recruiting
- Conditions
- Skin Resurfacing
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT07214272
- Locations
- 🇺🇸
Dermatology Cosmetic Laser Associates of La Jolla, Inc. d/b/a West Dermatology Research Center, La Jolla, California, United States
🇺🇸Miami Dermatology & Laser Research LLC, Miami, Florida, United States
🇺🇸Oak Dermatology, LLC, Naperville, Illinois, United States
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
Recruiting
- Conditions
- Acne Vulgaris
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT07205107
- Locations
- 🇨🇦
CHARM Site 005, Toronto, Ontario, Canada
A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment
Not Applicable
Not yet recruiting
- Conditions
- WrinkleLax SkinLines Skin
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT07187297
- Locations
- 🇺🇸
Union Square Laser Dermatology, New York, New York, United States
Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis
Phase 4
Not yet recruiting
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Matching placebo rectal foam
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05976802
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Phase 3
Active, not recruiting
- Conditions
- Hepatic Encephalopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 466
- Registration Number
- NCT05297448
- Locations
- 🇺🇸
Bausch Site 591, Homewood, Alabama, United States
🇺🇸Bausch Site 445, Chandler, Arizona, United States
🇺🇸Bausch Site 453, Sun City, Arizona, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 42
- Next
News
No news found